Searchable abstracts of presentations at key conferences in endocrinology

ea0038oc4.3 | Diabetes and cardiometabolic complications | SFEBES2015

5α-tetrahydrocorticosterone exhibits topical anti-inflammatory action with limited adverse effects on angiogenesis

Gastaldello Annalisa , Livingstone Dawn E , Tsang Nicola , Walker Brian R , Hadoke Patrick W , Andrew Ruth

Background: The 5α-reduced glucocorticoid, 5α-tetrahydrocorticosterone (5α-THB), displays a dissociated steroid profile exhibiting anti-inflammatory effects in a murine model of thioglycollate-induced peritonitis but failing to induce adverse metabolic effects caused by corticosterone. We assessed the topical anti-inflammatory properties of 5α-THB in a model of irritant dermatitis. Given the adverse effects of steroids on cutaneous wound healing, we also in...

ea0013p167 | Diabetes, metabolism and cardiovascular | SFEBES2007

11β-Hydroxysteroid dehydrogenase-1: key regulator in oxysterol metabolism?

Mitic Tijana , McNae Iain , Webster Scott P , Wamil Malgorzata , Walker Brian R , Hadoke Patrick W F , Andrew Ruth

7-Oxysterols modulate lipid transport and promote oxidative stress and apoptosis in the vascular wall. 7-Ketocholesterol (7KC) and 7β-hydroxycholesterol (7βOHC) are inter-converted by 11β-hydroxysteroid dehydrogenase-1 (11βHSD1), better known for metabolising glucocorticoids. Pharmacological inhibition of 11βHSD1 protects against atherosclerosis and these beneficial effects may be mediated through changes in glucocorticoids or oxysterols. To establish ...

ea0025oc1.5 | Young Endocrinologists prize session | SFEBES2011

Atheroprotection by 11β-HSD1 deficiency in ApoE−/− mice: role of both glucocorticoid and 7-oxysterol factors

Mitic Tijana , Hadoke Patrick W F , Chuaiphichai Surawee , Man Taq Y , Miller Eileen , Andrew Ruth , Walker Brian R , Chapman Karen E , Seckl Jonathan R

11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) regenerates active glucocorticoids thus amplifying their intracellular actions. 11β-HSD1 deficiency or inhibition, which improve metabolic syndrome and attenuate atherosclerosis in vulnerable rodent strains, is a target for drug development. However, 11β-HSD1 also converts 7-ketocholesterol (7KC) (which accumulates in fatty tissues), to the potentially more atherogenic, 7β-hydroxycholesterol. Whether a...